New hope for kids with hodgkin lymphoma: modified chemo regimen tested in china
NCT ID NCT04726501
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a modified chemotherapy regimen (based on a U.S. protocol) in 200 Chinese children and teens with newly diagnosed Hodgkin lymphoma. Depending on risk level, patients receive 4 to 6 cycles of chemotherapy, with or without low-dose radiation. The goal is to see if this approach can improve event-free survival and overall survival in this population.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Combination chemotherapy (AVE-PC or ABVE-PC) with or without involved-field radiotherapy
What this could lead to
If successful, this could confirm that a modified COG protocol works well for Chinese children with Hodgkin lymphoma, potentially improving event-free and overall survival rates.
What could go wrong
This is a single-country, non-randomized study with only 200 participants, so results may not apply broadly. Chemotherapy and radiotherapy carry risks like infection, organ damage, and secondary cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nanjing Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Nanjing, China
-
Shanghai Children's Medical Center
Shanghai, 200127, China
-
West China Second University Hospital, Sichuan University, Chengdu, China
Chengdu, China